| Original language | English |
|---|---|
| Journal | Leukemia |
| Volume | 34 |
| Issue number | 8 |
| Pages (from-to) | 2234-2237 |
| Number of pages | 4 |
| ISSN | 0887-6924 |
| DOIs | |
| Publication status | Published - 01.08.2020 |
Funding
Acknowledgements This study was funded by Italfarmaco S.p.A. David Young of Young Medical Communications and Consulting Ltd, a medical writer supported by funding from Italfarmaco S.p.A., provided drafts and editorial assistance to the authors during preparation of this paper. The authors would like to thank the investigators who recruited patients, including Dr Andrzej Hellmann, and the patients at the investigative sites for their support of this study. Conflict of interest AR has received honoraria for consultancy, and travel support from Italfarmaco, Gilead, Amgen, Novartis, Pfizer, Celgene, Sanofi, Astellas and Roche. AI has received speaker honoraria from Novartis, Pfizer and Incyte. AMV has received honoraria for advisory board participation from Novartis, Celgene, Incyte, CTI and Italfarmaco, and for lectures from Novartis, and CTI. N.v.B. received research funding from Novartis. MFM has received honoraria and has attended advisory boards with Novartis, and has received honoraria from Celgene. RAM has received honoraria as a consultant to Novartis, Sierra Oncology, and La Jolla Oncology, and research support from Incyte, Genentech, Celgene, CTI, and Abbvie. RT has advised and received honoraria from Italfarmaco. PB, SM, and SDT are employees of Italfarmaco SpA, the sponsor of the study. RN, AG, BM, AP, GC, MDM, SL, NC, J-PM, APancrazzi, FG have no conflicts to disclose.
